Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice

Abstract Patients with type 2 diabetes (T2D) have decreased butyrate-producing bacteria. We hypothesized that supplementation with butyrate-producing bacteria may exert beneficial effects on T2D. The current study investigated the effects of well-characterized butyrate-producing bacteria Clostridium...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lingling Jia, Dongyao Li, Ninghan Feng, Muhammad Shamoon, Zhenghua Sun, Lei Ding, Hao Zhang, Wei Chen, Jia Sun, Yong Q Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/307d3e58f5bf4547ae517a56c4b97278
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:307d3e58f5bf4547ae517a56c4b97278
record_format	dspace
spelling	oai:doaj.org-article:307d3e58f5bf4547ae517a56c4b972782021-12-02T15:06:23ZAnti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice10.1038/s41598-017-07335-02045-2322https://doaj.org/article/307d3e58f5bf4547ae517a56c4b972782017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07335-0https://doaj.org/toc/2045-2322Abstract Patients with type 2 diabetes (T2D) have decreased butyrate-producing bacteria. We hypothesized that supplementation with butyrate-producing bacteria may exert beneficial effects on T2D. The current study investigated the effects of well-characterized butyrate-producing bacteria Clostridium butyricum CGMCC0313.1 (CB0313.1) on hyperglycemia and associated metabolic dysfunction in two diabetic mouse models. CB0313.1 was administered daily by oral gavage to leptin db/db mice for 5 weeks starting from 3 weeks of age, and to HF diabetic mice induced by high fat diet (HFD) plus streptozotocin (STZ) in C57BL/6J mice for 13 weeks starting from 4 weeks of age. CB0313.1 improved diabetic markers (fasting glucose, glucose tolerance, insulin tolerance, GLP-1 and insulin secretion), and decreased blood lipids and inflammatory tone. Furthermore, CB0313.1 reversed hypohepatias and reduced glucose output. We also found that CB0313.1 modulated gut microbiota composition, characterized by a decreased ratio of Firmicutes to Bacteroidetes, reduced Allobaculum bacteria that were abundant in HF diabetic mice and increased butyrate-producing bacteria. Changes in gut microbiota following CB0313.1 treatment were associated with enhanced peroxisome proliferator–activated receptor-γ (PPARγ), insulin signaling molecules and mitochondrial function markers. Together, our study suggests that CB0313.1 may act as a beneficial probiotic for the prevention and treatment of hyperglycemia and associated metabolic dysfunction.Lingling JiaDongyao LiNinghan FengMuhammad ShamoonZhenghua SunLei DingHao ZhangWei ChenJia SunYong Q ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-15 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lingling Jia Dongyao Li Ninghan Feng Muhammad Shamoon Zhenghua Sun Lei Ding Hao Zhang Wei Chen Jia Sun Yong Q Chen Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice
description	Abstract Patients with type 2 diabetes (T2D) have decreased butyrate-producing bacteria. We hypothesized that supplementation with butyrate-producing bacteria may exert beneficial effects on T2D. The current study investigated the effects of well-characterized butyrate-producing bacteria Clostridium butyricum CGMCC0313.1 (CB0313.1) on hyperglycemia and associated metabolic dysfunction in two diabetic mouse models. CB0313.1 was administered daily by oral gavage to leptin db/db mice for 5 weeks starting from 3 weeks of age, and to HF diabetic mice induced by high fat diet (HFD) plus streptozotocin (STZ) in C57BL/6J mice for 13 weeks starting from 4 weeks of age. CB0313.1 improved diabetic markers (fasting glucose, glucose tolerance, insulin tolerance, GLP-1 and insulin secretion), and decreased blood lipids and inflammatory tone. Furthermore, CB0313.1 reversed hypohepatias and reduced glucose output. We also found that CB0313.1 modulated gut microbiota composition, characterized by a decreased ratio of Firmicutes to Bacteroidetes, reduced Allobaculum bacteria that were abundant in HF diabetic mice and increased butyrate-producing bacteria. Changes in gut microbiota following CB0313.1 treatment were associated with enhanced peroxisome proliferator–activated receptor-γ (PPARγ), insulin signaling molecules and mitochondrial function markers. Together, our study suggests that CB0313.1 may act as a beneficial probiotic for the prevention and treatment of hyperglycemia and associated metabolic dysfunction.
format	article
author	Lingling Jia Dongyao Li Ninghan Feng Muhammad Shamoon Zhenghua Sun Lei Ding Hao Zhang Wei Chen Jia Sun Yong Q Chen
author_facet	Lingling Jia Dongyao Li Ninghan Feng Muhammad Shamoon Zhenghua Sun Lei Ding Hao Zhang Wei Chen Jia Sun Yong Q Chen
author_sort	Lingling Jia
title	Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice
title_short	Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice
title_full	Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice
title_fullStr	Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice
title_full_unstemmed	Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice
title_sort	anti-diabetic effects of clostridium butyricum cgmcc0313.1 through promoting the growth of gut butyrate-producing bacteria in type 2 diabetic mice
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/307d3e58f5bf4547ae517a56c4b97278
work_keys_str_mv	AT linglingjia antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT dongyaoli antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT ninghanfeng antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT muhammadshamoon antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT zhenghuasun antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT leiding antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT haozhang antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT weichen antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT jiasun antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice AT yongqchen antidiabeticeffectsofclostridiumbutyricumcgmcc03131throughpromotingthegrowthofgutbutyrateproducingbacteriaintype2diabeticmice
_version_	1718388440593072128

Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice

Ejemplares similares